Amgen’s experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial.

Amgen’s experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial.

Amgen reported a far better than expected quarterly profit as sales of its anemia drug Aranesp rebounded from the preceding quarter.

The biotechnology company reported a successful trial for an experimental osteoporosis drug, which reduced the risk of bone fractures in post-menopausal women.

The biotechnology company reported a successful trial for an experimental osteoporosis drug, which reduced the risk of bone fractures in post-menopausal women.